Clear Search

Showing 1 result for “Gibson KA”.

July 2023

Eficacia comparativa de baricitinib en primera línea en pacientes con artritis reumatoide en el conjunto de datos australiano OPAL

ACR Open Rheumatol. 2023;5(7):345-353 doi 10.1002/acr2.11577

Cicirello, et al. present results showing that baricitinib is comparable in treatment persistence with TNF inhibitors. However, treatment persistence up to 24 months was significantly longer for baricitinib, but the effect size of one month is not clinically meaningful.